NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient group
pharmaphorum
JUNE 2, 2021
NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA UK. “NICE’s initial ‘no’ to approving risdiplam for NHS funding is not unexpected,” said SMA UK this morning.
52 
Let's personalize your content